HIV-1 plasma viremia not increased in patients receiving highly active antiretroviral therapy after influenza vaccination.
The effect of vaccinating patients with sustained undetectable HIV-1 viremia (VL) achieved with highly active antiretroviral therapy was prospectively investigated. During the 1998 influenza immunization period, 39 HIV-1-infected patients who showed a VL<20 copies/ml for at least 6 months before the study entry date were vaccinated for influenza. Twenty-two vaccinees were immunized at entry. Seventeen controls were followed for 4 weeks after entry, crossing over then to the vaccination group. The proportion of patients with undetectable VL was not significantly different between the vaccination and control groups 2 and 4 weeks after entry. Therefore, influenza immunization of patients with undetectable viremia achieved with highly active antiretroviral therapy does not seem to affect VL.
Macías
J
J
Servicio de Medicina Interna, Hospital Universitario Virgen de Valme, Seville, Spain. jmacias@cica.es
Pineda
J A
JA
Leal
M
M
Abad
M A
MA
Delgado
J
J
Rosa
R
R
Rubio
A
A
Sánchez-Quijano
A
A
Lissen
E
E
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018592:Cross-Over Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage*; D008297:Male; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy / Q000276:immunology*; D014779:Virus Replication / Q000187:drug effects
D007252:Influenza Vaccines; D012367:RNA, Viral